Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

Background Factor XI (FXI) inhibition offers the promise of hemostasis‐sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the inactive zymoge...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thrombosis and haemostasis 2022-02, Vol.20 (2), p.307-315
Hauptverfasser:	Yi, B. Alexander, Freedholm, Debra, Widener, Nancy, Wang, Xiaohui, Simard, Emilie, Cullen, Constance, Al‐Saady, Naab M., Lepor, Norman E., Coulter, Sara, Lovern, Mark, Bloomfield, Dan
Format:	Artikel
Sprache:	eng
Schlagworte:	antibodies, monoclonal Antibodies, Monoclonal, Humanized - pharmacology Antiplatelet therapy blood Blood Coagulation Tests Cardiac arrhythmia Coagulation factors Factor XI Factor XIa Fibrillation HAEMOSTASIS Hemostasis Humans Intravenous administration Monoclonal antibodies Original Patients Pharmacodynamics Pharmacokinetics Placebos Proenzymes Safety Thromboembolism Thromboplastin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!